# Multiomics analyses of human colorectal cancer reveal changes in mitochondrial metabolism associated with chemotherapy resistance

**Authors:** Shiyi Chen, Qian Li, Wei Zheng

PMC · DOI: 10.3389/fonc.2025.1625797 · Frontiers in Oncology · 2025-11-10

## TL;DR

This study shows how mitochondrial metabolism changes in colorectal cancer cells that resist chemotherapy, offering new insights into potential treatments.

## Contribution

The study identifies specific mitochondrial metabolic changes linked to chemotherapy resistance in colorectal cancer cells.

## Key findings

- 185 proteins and 1099 metabolites were dysregulated in chemotherapy-resistant CRC cells.
- Key metabolic pathways like pyrimidine and TCA cycles are associated with chemotherapy resistance.
- Mitochondrial morphology changes include increased number, length, and area in resistant cells.

## Abstract

Mitochondria are essential organelles involved in energy production, cellular metabolism, and signal transduction. They have important impacts on tumorigenesis and cancer progression. Nevertheless, the associations between mitochondrial metabolic processes and chemotherapy resistance in colorectal cancer (CRC) are not well understood.

We generated a chemotherapy-resistant colorectal cancer cell line, HCT-15/DOX, via doxorubicin (DOX) induction. We then performed proteomic and metabolomic analyses via LC-MS/MS technology on both the parental and the DOX-resistant cell lines. Additionally, transmission electron microscopy was used to examine changes in mitochondrial morphology between the two cell lines.

The results revealed significant dysregulation of 185 proteins and 1099 metabolites in HCT-15/DOX cells relative to parental cells, highlighting the impact of chemotherapy resistance on cellular processes. The key functional proteins that were identified included upregulated SDHA, BCKDHB, CRYZ, NUDT6, CPT1A, and POLG, and downregulated CRAT, FDPS, SFXN1, and ATAD3B. Additionally, through combined multiomics pathway enrichment analysis, pyrimidine metabolism, purine metabolism, ascorbate and aldarate metabolism, propanoate metabolism, and the citrate cycle (TCA cycle) were identified as important metabolic processes associated with CRC chemotherapy resistance. Transmission electron microscopy analysis revealed that HCT-15/DOX cells had increased mitochondrial number, length, and area.

This research highlights notable differences in mitochondrial morphology and diverse mitochondrial metabolic functions between parental and DOX-resistant HCT-15 CRC cells. The findings of the present study provide insights into the mitochondrial metabolic changes associated with CRC chemotherapy resistance, offering valuable insights into the mechanisms underlying these changes and identifying potential therapeutic targets for addressing CRC chemotherapy resistance.

## Linked entities

- **Genes:** SDHA (succinate dehydrogenase complex flavoprotein subunit A) [NCBI Gene 6389], BCKDHB (branched chain keto acid dehydrogenase E1 subunit beta) [NCBI Gene 594], CRYZ (crystallin zeta) [NCBI Gene 1429], NUDT6 (nudix hydrolase 6) [NCBI Gene 11162], CPT1A (carnitine palmitoyltransferase 1A) [NCBI Gene 1374], POLG (DNA polymerase gamma, catalytic subunit) [NCBI Gene 5428], CRAT (carnitine O-acetyltransferase) [NCBI Gene 1384], FDPS (farnesyl diphosphate synthase) [NCBI Gene 2224], SFXN1 (sideroflexin 1) [NCBI Gene 94081], ATAD3B (ATPase family AAA domain containing 3B) [NCBI Gene 83858]
- **Proteins:** SDHA (succinate dehydrogenase complex flavoprotein subunit A), BCKDHB (branched chain keto acid dehydrogenase E1 subunit beta), CRYZ (crystallin zeta), NUDT6 (nudix hydrolase 6), CPT1A (carnitine palmitoyltransferase 1A), POLG (DNA polymerase gamma, catalytic subunit), CRAT (carnitine O-acetyltransferase), FDPS (farnesyl diphosphate synthase), SFXN1 (sideroflexin 1), ATAD3B (ATPase family AAA domain containing 3B)
- **Chemicals:** doxorubicin (PubChem CID 31703), DOX (PubChem CID 31703)
- **Diseases:** colorectal cancer (MONDO:0005575), CRC (MONDO:0005575)

## Full-text entities

- **Genes:** POLG (DNA polymerase gamma, catalytic subunit) [NCBI Gene 5428] {aka MIRAS, MTDPS4A, MTDPS4B, PEO, POLG1, POLGA}, CRYZ (crystallin zeta) [NCBI Gene 1429], SDHA (succinate dehydrogenase complex flavoprotein subunit A) [NCBI Gene 6389] {aka CMD1GG, FP, MC2DN1, NDAXOA, PGL5, PPGL5}, NUDT6 (nudix hydrolase 6) [NCBI Gene 11162] {aka ASFGF2, FGF-AS, FGF2AS, GFG-1, GFG1}, ATAD3B (ATPase family AAA domain containing 3B) [NCBI Gene 83858] {aka AAA-TOB3, TOB3}, CRAT (carnitine O-acetyltransferase) [NCBI Gene 1384] {aka CAT, CAT1, NBIA8}, BCKDHB (branched chain keto acid dehydrogenase E1 subunit beta) [NCBI Gene 594] {aka BCKDE1B, BCKDH E1-beta, E1B, MSUD1B, OVD1B}, FDPS (farnesyl diphosphate synthase) [NCBI Gene 2224] {aka FPPS, FPS, POROK9}, CPT1A (carnitine palmitoyltransferase 1A) [NCBI Gene 1374] {aka CPT I, CPT1, CPT1-L, CPTI-L, L-CPT1}, SFXN1 (sideroflexin 1) [NCBI Gene 94081] {aka SLC56A1, TCC}
- **Diseases:** CRC (MESH:D015179), cancer (MESH:D009369)
- **Chemicals:** purine (MESH:C030985), aldarate (-), citrate (MESH:D019343), ascorbate (MESH:D001205), propanoate (MESH:D011422), TCA (MESH:D014238), DOX (MESH:D004317), pyrimidine (MESH:C030986)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** HCT-15 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0292)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12640853/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12640853/full.md

## References

54 references — full list in the complete paper: https://tomesphere.com/paper/PMC12640853/full.md

---
Source: https://tomesphere.com/paper/PMC12640853